Telomerase, a critical enzyme responsible 'for cellular immortality, is usually repressed in somatic cells except for lymphocytes and self-renewal cells, but is activated in approximately 85% of human cancer tissues. The human telomerase reverse transcriptase (hTERT) is the catalytic component of human telomerase. In cancers in which telomerase activation occurs at the early stages of the disease, telomerase activity and hTERT expression are useful markers for the detection of cancer cells. In other cancers in which telomerase becomes upregulated upon tumor progression, they are useful as prognostic indicators. However, careful attention should be paid to false-negative results caused by the instability of telomerase and of the hTERT mRNA and the presence of PCR inhibitors, as well as to false-positive results caused by the presence of alternatively spliced hTERT mRNA and normal cells with telomerase activity. Recently, methods for the in situ detection of the hTERT mRNA and protein have been developed. These methods should facilitate the unequivocal detection of cancer cells, even in tissues containing a background of normal telomerase-positive cells.
Introduction
Mammalian telomeres are made of many hundreds to thousands units of the simple DNA repeat TTAGGG. Telomeres form a nucleoprotein that cap and protect the ends of linear chromosomes. Because the DNA replication machinery cannot fully replicate the ends of linear DNA molecules, telomeres progressively shorten with each cell division (Watson 1972) . Eventually, when a critically short telomere length is reached, cells stop dividing and senesce (Greider 1990; Wright and Shay 1992 ). This phenomenon is thought to function as a 'mitotic clock' that limits the lifespan of individual cells. Telomerase is a specialized reverse transcriptase that synthesizes telomeric repeats onto chromosomal ends and thus compensates for the progressive shortening of the telomeres caused by the end-replication problem (Lingner et al. 1995) . This enzyme lacks from most somatic human cells and is typically restricted to certain specialized cell types, such as germ cells and stem/progenitor cells of self-renewal tissues, which must perform unusually large numbers of cell divisions (Hiyama et al. 1995c; Wright et al. 1996; Sakabe et al. 1998) .
Cancer is a disease characterized by uncontrolled proliferation and invasion into surrounding tissues or distant organs. Most somatic human cells lack telomerase activity, have a limited life span, and require the activation of telomerase for unlimited proliferation. Although telomerase activation is not always concomitant with carcinogenesis, its presence in 85% of more than 3000 tumor samples tested makes telomerase activity the most universal maker of human cancers (Kim 1997; Shay and Gazdar 1997; Dhaene et al. 2000) . Recent reports revealed that telomerase activity is upregulated during mouse tumorigenesis in spite of the fact that mice have very long telomeres (Blasco et al. 1996; Broccoli et al. 1996) . This observation and others have suggested that telomerase may promote tumorigenesis independently of telomere length. By stabilizing telomeres and supporting the indefinite growth of most cancer cells, telomerase most certainly plays a crucial role in the progression and maintenance of tumors.
An important question, is when telomerase is activated during the multi-step process of carcinogenesis. In some instances, telomerase may already be ubiquitously expressed at the preneoplastic or in situ stage; while in other instances, the enzyme may be activated gradually with cancer progression (Shay and Bacchetti 1997) . These differences are crucial in dictating whether telomerase might be clinically useful for either diagnostic or prognostic purposes. Although most somatic human cells lack telomerase activity, some tissues contain specialized cells, including germ cells, lymphocytes, stem cells, or certain epithelial cells, that display weak levels of telomerase activity, which can be upregulated concomitantly with growth signals. In such tissues, in situ immunohistochemical detection of telomerase may be necessary to determine whether telomerase expression is derived from normal telomerase-positive cells or from cancer cells. Taking these key points into account, telomerase is now being explored as a novel marker for early detection and/or the grading of malignant tumors. The present article reviews the use of human telomerase as a cancer diagnostic marker and as a prognostic tool for predicting the outcome of individual patients.
Detecting human telomerase in clinical materials
Telomerase can be measured by a PCR-based assay called telomeric repeat amplification protocol (TRAP) (Kim et al. 1994 ). The assay is quite sensitive and can detect as few as 10 telomerase positive cells (Wright et al. 1995) . With this high sensitivity, telomerase activity can also be detected in certain normal somatic tissues, especially in proliferative and/or stem cells of self-renewing tissues (such as intestinal epithelium) and activated lymphocytes (Hiyama et al. 1995c (Hiyama et al. , 1996b Wright et al. 1996) . Moreover, this activity is also detectable, albeit at low levels, in some benign tumors such as fibroadenomas of the breast (Hiyama et al. 1996a) , hyperplastic nodule/adenomas of the thyroid (Matthews et al. 2001) , and colon adenomas (Hiyama et al. 1996b) . As a general rule, telomerase activity in normal somatic cells tends to be much lower in comparison to that detected in cancer cells. In clinical samples from tissues containing normal telomerase-positive cells, evidence of cancer cells requires levels of telomerase activity that are significantly higher than those of matched control tissues (Shay and Bacchetti 1997) . As the TRAP assay is based on semi-quantitative PCR, a more precise method of quantification might be needed for such samples. To overcome this limitation, a real-time PCR assay (RTQ-TRAP) has been developed that allows quantitative measurements of telomerase activity in tissue samples (Hou et al. 2001) . To avoid false-positive results due to contamination of cell samples with lymphocytes, we recommended using a thousand cell equivalents of cell lysate per assay, as proteins extracted from a thousand adult lymphocytes do not produce detectable telomerase activity (Hiyama et al. 1995c; Iwao et al. 1997) . To avoid false-negative results, careful attention should be paid to the stability of telomerase and the presence of PCR inhibitors when examining clinical specimens.
Human telomerase activity is associated with the expression of two major components: human telomerase RNA (hTR) (Feng et al. 1995) and human telomerase reverse transcriptase (hTERT) (Nakamura et al. 1997) . Recent studies have targeted the expression of these two components as surrogates for telomerase activity and discussed their value as tumor markers. Since hTR is expressed at low levels in all cells, including cells that lack telomerase activity (Koyanagi et al. 2000) , detection of the hTERT mRNA is believed to be a more reliable marker of the presence of cancer cells in clinical samples. However, the existence of splicing variants of the hTERT mRNA that fail to produce telomerase activity (Ulaner et al. 1998) can also be problematic for the use of the hTERT mRNA as surrogate for telomerase activity.
Telomerase as a diagnostic marker
Recently, there has been an increasing amount of experimental data on the detection of telomerase activity and/or hTERT expression in clinical materials as a diagnostic tool for various cancers (Table 1) .
Head and neck tumors
Most cancer tissues in head and neck lesions show high levels of telomerase expression. Although the viability of cancer cells in these specimens is not particularly high, telomerase activity is often detected in oral washings of patients with oral malignancy (Califano et al. 1996; Sumida et al. 1998 ). In such specimens, it is difficult to avoid contamination by substances that interfere with PCR, such as necrotic tissue, leukocytes, erythrocytes, dental plaque, and bacteria. The presence of these substances in cancer samples can lead to false-negative results. Although currently limited in its sensitivity, the detection of telomerase activity or hTERT mRNA in oral washings is a novel marker indicating the presence of cancer cells shed from the upper aerodigestive tract.
In tumor biopsies, telomerase activity and the hTERT mRNA are almost always detected at high levels. Since low levels of telomerase activity are detected in the normal buccal epithelia and in approximately 20% of non-cancerous biopsy samples, a quantitative TRAP assay may be required for cancer diagnosis.
Thyroid and breast tumors
Because thyroid and breast lesions are easily palpable, fine needle aspiration (FNA) is widely used as a diagnostic tool for cancer detection in these lesions. For tumors of the thyroid gland, differential diagnosis between follicular adenoma and adenocarcinoma is difficult by FNA cytology alone. The detection of telomerase activity and/or hTERT mRNA has been found to be a useful tool for this differential diagnosis; as cancers gave positive signals while adenomas were negative for telomerase expression Zeiger et al. 1999) . However, thyroid tissues often contain lymphocytes, so that telomerase activity and hTERT mRNA derived from these inflammatory cells may also be detectable in certain benign diseases, such as Hashimoto thyroiditis (Haugen et al. 1997) .
In the breast, normal mammary tissue lacks detectable telomerase activity, while the activity is expressed in 80-90% of ductal carcinoma in situ (DCIS) lesions and 90% of invasive breast cancers (Hiyama et al. 1996a; Umbricht et al. 1999 ). hTERT mRNA is detected at high frequency in breast cancers, where its levels are relatively high (Bieche et al. 2000) . One of the most common problems in using telomerase for breast cancer diagnosis is the presence of telomerase activity in benign fibroadenomas. Approximately 40% of fibroadenoma tissues display low-level telomerase activity (Hiyama et al. 1996a; Pearson et al. 1998 ). In combination with cytology and with careful attention to benign diseases, the screening of FNA samples for telomerase expression is likely to become a powerful tool for the detection of breast and thyroid cancers (Pearson et al. 1998; Mokbel et al. 1999; Poremba et al. 1999a; Hiyama et al. 2000) .
Lung and mediastinum
Sputum, bronchoalveolar lavage (BAL), bronchial brushing, and bronchial washing samples have all been tested in the TRAP assay for the detection of lung cancer cells (Sen et al. 2001) . Use of the TRAP assay on sputum samples might hold potential for the early and non-invasive diagnosis of lung cancer. However, since sputum contains an abundance of mucus, which interferes with PCR and other enzyme reactions, the sensitivity of the telomerase assay in sputum is unsatisfactory for the detection of cancer (Sen et al. 2001) . In brushing or BAL samples, on the other hands, telomerase activity showed a relatively high sensitivity for the detection of lung cancer cells, but more so for squamous cell carcinoma than for adenocarcinoma. However, BAL samples can contain activated lymphocytes, which can give false-positive results in benign diseases. The clonal expansion of lymphocytes, in particular, can produce strong telomerase activity in BAL samples (Haruta et al. 1999) , which may instead reflect the aggressiveness of autoimmunity in certain benign diseases (Hiyama et al. 1998) .
Several attempts to detect telomerase activity or hTERT mRNA have been reported using pleural effusion and mediastinal lymph node aspiration samples Braunschweig et al. 2001; Dejmek et al. 2001; Wallace et al. 2003) . Because carcinomas from almost any tumor sites can metastasize to the pleura, pleural effusions These percentages were calculated from the review papers Dhaene et al. (2000) , Hiyama (2002, 2003) and Orlando et al. (2001) and recent numerous reports in addition to our unpublished data. Abbreviations: BAL, bronchoalveolar lavage; FNA, fine needle aspirates. a Voiding urine after massage.
may contain cancer cells originating from other organs such as the breast, ovary, or gastrointestinal tract. In malignant pleural effusions diagnosed by either fluid cytology or pleural biopsy, Yang et al. (1998) detected telomerase activity in 91% of cases with a specificity of 94%, indicating that the measurement of telomerase activity is a useful adjunct to cytology for detecting cancer cells. In this study, the only false positives were three samples from patients with tuberculosis. Thus, in pleural effusions as well as BAL samples, the sensitivity of the telomerase assay for detecting cancer cells is relatively high, with most of the false-positive signals being caused by lymphocytes contamination of non-cancerous lesions.
Digestive organs and peritoneum
Cancers of the digestive system are frequently diagnosed by endoscopic examination. In biopsies of the esophagus, telomerase activity was present in almost all esophageal cancers but was also detected in more than half of non-cancerous tissues, where the activity can be found in the normal epithelial basal cells. Similar results were obtained for biopsies of the stomach and colon. The sensitivity of telomerase activity or hTERT mRNA expression for detecting cancerous lesions was high, but telomerase was also present, albeit at lower levels, in non-cancerous tissues, where it localizes to the basal cells of crypts (Hiyama et al. 1996b ). Hence, a more precise measurement of the level of telomerase activity in biopsy samples of the gut may be necessary for the diagnosis of cancers. Cells derived from colon luminal washing can also be applied to the TRAP assay for cancer diagnosis. Because washing samples rarely contain basal crypt cells, the specificity of the TRAP assay for colon washing samples was remarkable but at the expense of sensitivity, which was found to be relatively low (Yoshida et al. 1997 ).
In liver biopsies, detection of telomerase activity or hTERT mRNA shows promises for cancer diagnosis, albeit low-level expression of these markers was also reported in non-cancerous tissues . In pancreatico-biliary cancers, detection of telomerase activity or hTERT mRNA in biopsy samples displayed a high sensitivity for cancer diagnosis. With the exception of pancreatic juice, the assay had a sensitivity that was low for excretion and secretion samples, such as bile (Itoi et al. 1999 (Itoi et al. , 2001 . In patients with pancreatic ductal adenocarcinomas, the pancreatic juice contains freshly exfoliated ductal cells that carry very high levels of telomerase activity. Because of its high sensitivity and specificity, the detection of telomerase activity and/or hTERT mRNA in pancreatic juice has become a promising new application of cancer diagnosis (Hiyama et al. 1997b; Iwao et al. 1997; Suehara et al. 1997; Morales et al. 1998) . Moreover, detection of telomerase activity in pancreatic juice was additionally useful for the differential diagnosis of benign and malignant intraductal papillary mucinous tumors (IPMT) of the pancreas, which can be difficult to distinguish preoperatively (Inoue et al. 2001; Uemura et al. 2003) .
Because peritoneal dissemination usually occurs in advanced stages of digestive cancers, telomerase activity in peritoneal lavage samples also showed a high specificity for cancer cell detection. Tangkijvanich et al. (1999) measured telomerase activity in nonmalignant and malignancy-related ascites associated with hepatocellular carcinoma and peritoneal carcinomatosis. Both the sensitivity and specificity of the telomerase assay were higher than those of cytology for diagnosis of the malignancy. The incidence of false-positive for telomerase activity was only of 4%, and all of these false positives showed evidence of lymphocytic contamination. Duggan et al. (1998) also found telomerase activity to be more sensitive than cytology in ascitic samples obtained from patients with ovarian cancer.
Genitourinary organs
Among exfoliating materials, voiding urine is easiest to examine. For the detection of bladder cancer using voided urine samples obtained from bladder cancer patients and controls, the TRAP assay showed the highest sensitivity (67%) and specificity (99%) Ramakumar et al. (1999) . Since the viability of cells in voided urine samples varies, the sensitivity of telomerase activity for cancer diagnosis was lower than specificity. As an alternative, high sensitivity could be obtained in urine samples by detection of the hTERT mRNA by RT-PCR (Ito et al. 1998; Fukui et al. 2001) . While telomerase activity and hTERT mRNA might both be useful for the detection of cancer cells in bladder washings, detection of the hTERT mRNA may be preferable for the screening of voided urine Fukui et al. 2001) .
In voided urine samples obtained after prostate massage, the sensitivity of telomerase activity was higher than that of cytologic examination for the detection of prostate cancer (Meid et al. 2001) . As a surrogate for unstable telomerase, hTERT mRNA was an even more reliable marker. They reported that the addition of EDTA to a final concentration of 20 mmol/l stabilized the RNA for up to 2 h at 4°C.
As a potential biomarker of cervical dysplasia, telomerase has also been the focus of intense investigations. In cervical cancers, whether telomerase is activated in pre-malignant lesions remains controversial. According to several studies published on cervical biopsies (Wisman et al. 1998; Zheng et al. 2000; Jarboe et al. 2002) , telomerase activity is abnormally present in a remarkably high proportion of high-grade squamous intraepithelial lesions (HSILs), indicating that the activation of telomerase is an early event in the malignant progression of cervical lesions. Still, a more complex situation has been suggested by histochemical studies, which revealed that the hTERT protein was present in the lower suprabasal levels of the normal cervical mucosa (Frost et al. 2000) . In cancers, the hTERT protein was relocalized to virtually all levels of the lesional epithelia, concomitantly with the aberrant reexpression of telomerase activity. Thus, for the diagnosis of cervical cancers, a more precise measurement of telomerase activity might be needed, which should be confirmed by the histochemical staining of mirror image specimens. Thus, the detection of in situ carcinomas and precancerous lesions in cervical biopsies would likely require the application of methodologies for the in situ detection of the hTERT mRNA or protein, as described later in this review.
Skin
Skin is a surface organ from which biopsy specimens are easily prepared. Investigations of telomerase activity as a marker of skin cancer showed that epidermal basal cells had low levels of telomerase activity; that telomerase was not activated in the vast majority of squamous cell carcinoma; but that most cutaneous malignant melanoma displayed high-levels of telomerase activity (Parris et al. 1999) . To elucidate the correlation between carcinogenesis and telomerase activation in the skin, further studies on skin cancers and related lesions are necessary.
Circulating cancer cells
Irrespective of the tumor type, the blood of cancer patients is likely to contain circulating cancer cells that could potentially be detected using the telomerase assay (Gauthier et al. 2001) . The detection of these rare cancer cells in whole blood samples would be predicted to be masked by the potential presence of activated lymphocytes expressing high levels of telomerase activity (Hiyama et al. 1995c; Haruta et al. 1999) . To detect circulating carcinoma cells using the telomerase assay, immunomagnetic separation can first be used to isolate epithelial cells from peripheral blood mononuclear cells, after which point the harvested cells can be tested for telomerase activity. In one report, the harvested circulating epithelial cells showed telomerase activity in 70-80% of patients with advanced lung, colon, and breast cancers, suggesting that telomerase activity may become a useful clinical marker of circulating epithelial cancer cells (Gauthier et al. 2001) .
One of the most routinely collected bodily fluids is blood plasma, which can easily be prepared by centrifugation of whole blood. If tumor cells undergo necrosis and release their contents, some tumor-specific molecules might be present in plasma that could be detected. Although several studies have addressed the detection of tumorspecific mRNA in plasma, this broader topic is beyond the scope of this review. While it is unlikely that intact telomerase might be detected in plasma, a recent report has detected the hTERT mRNA and hTR in plasma (Chen et al. 2000) .
Hematopoietic malignancies
The presence of endogenous telomerase in normal hematopoietic stem cells and activated lymphocytes is an important confounding factor that can limit the value of the telomerase assay in the detection of hematopoietic malignancies. Blood samples from patients at the early stages of chronic lymphoid leukemia (CLL) display low-level telomerase activity, which progressively increases over the course of the disease to reach levels that are much higher than those detected in normal blood samples. Moreover, this increase is accompanied by a net decrease in telomere length . A series of 58 patients with CLL showed that higher telomerase activity and shorter telomeres were associated with an adverse prognosis (Bechter et al. 1998) . In chronic myeloid leukemia, telomerase activity is not increased over that of normal peripheral mononuclear cells, but decreases in telomere lengths are observed, which correlate with shorter intervals to the blast crisis phase (Iwama et al. 1997) . In acute lymphoblastic leukemia, smaller studies have found telomerase activity to be variable . With the exceptions of Hodgkin's lymphoma and chronic myeloid leukemia, all of acute myelogenous leukemia, multiple myeloma, plasma cell leukemia and non-Hodgkin's lymphoma exhibited marked increases in telomerase activity that were well above that of normal peripheral mononuclear cells (Norrback et al. 1998; Xu et al. 2001) .
In situ detection of the hTERT mRNA and protein When using RT-PCR or the TRAP assay to detect the hTERT mRNA or telomerase activity, the presence of normal telomerase-positive cells, such as lymphocytes or basal epithelial cells, can cause false-positive results. Methodology for the in situ detection of telomerase in individual cells would be expected to solve this problem. An in situ TRAP assay had previously been developed to detect the telomerase activity, but this methodology could only be used on fresh viable cells (Ohyashiki et al. 1997b ). The use of in situ hybridization (ISH) to detect components of the telomerase complex (hTR and hTERT mRNA), on the other hand, would be applicable to fixed tissues. However, hTR is also present at low levels in most cells lacking telomerase activity, and its level does not always correlate with telomerase activity. A better target for ISH detection would be the hTERT mRNA, whose levels appear to closely parallel those of telomerase activity.
For evaluating hTERT expression, several studies have reported the successful use of hTERT mRNA ISH (Chou et al. 2001; Kumaki et al. 2001) . While it is necessary to target sequences specific to the full-length mRNA to avoid false positives resulting from splice variants of hTERT mRNA, the ISH detection of the hTERT mRNA is predicted to become a powerful tool of cancer detection. For detecting hTERT expression, immunohistochemistry (IHC) can also be used to reveal the presence of the hTERT protein in a wide variety of clinical samples, including archival paraffin-embedded specimens (Hiyama et al. 2001; Kumaki et al. 2001 Kumaki et al. , 2002 . In spite of its very low abundance, the hTERT protein can now be detected in paraffin-embedded samples and core biopsies with the use of polyclonal or monoclonal antibodies in conjunction with appropriate antigen retrieval ( Figure 1 ) and/or the highly sensitive tyramide-based method of signal amplification (Frost et al. 2000) . Since IHC does not require specialized equipment for detection, hTERT IHC is predicted to become a powerful new technology for cancer detection. In most cancer tissues, the hTERT protein is heterogeneously distributed and, in some cases, can display regional variability. In most cancer specimens, the signal intensity of individual hTERT-positive cells did not differ substantially between tumors with high and low telomerase activity, and the level of telomerase activity was mainly dependent on the percentage of cells displaying hTERT expression (Hiyama et al. 2001) . This heterogeneity in telomerase expression appears to be an important factor dictating the overall levels of telomerase activity in tumors. With the availability of hTERT IHC, telomerase-positive cancer cells can now be detected in tissues containing a background of normal telomerase-positive cells. Likewise, Frost et al. (2000) have observed changes in the tissue distribution of the hTERT protein in cervical cancers: while the hTERT protein was limited to the lower suprabasal cells of the normal cervix, it was present at all levels of the lesional epithelium in moderate to severe dysplasia.
Telomerase in cancer prognosis and the grading of malignant tumors
In certain types of cancers, telomerase activity is upregulated during tumor progression, so that the level of telomerase activity can be used to evaluate the malignant grade of tumors and predict patient prognosis (Table 2 ). In certain cancers of the adults, the activation of telomerase correlates with advanced disease and poor prognosis, as in the cases of non-small cell lung cancer, gastric cancer, colorectal cancer, soft tissue tumors, and myelodysplastic disease (Chadeneau et al. 1995; Hiyama et al. 1995b; Marchetti et al. 1999; Tahara et al. 1999; Tatsumoto et al. 2000; Tomoda et al. 2002; Kido et al. 2003) . In patients with colorectal cancer (Tatsumoto et al. 2000) , including those undergoing curative resection of liver metastases (Smith et al. 2004) , both telomerase activity and hTERT mRNA expression could be used as independent prognostic factors. In a retrospective study of a large number of breast cancer patients, telomerase activity correlated with a more aggressive tumor phenotype and its level was highly predictive of clinical outcomes (Clark et al. 1997) . These findings suggest that telomerase activity is an useful indicator for identifying patients that would benefit from postoperative adjuvant chemotherapy.
Neuroblastomas are pediatric tumors that display a well-documented relationship between tumor biology and patient outcome. In these tumors, poor prognosis is associated with high levels of telomerase activity and full-length hTERT mRNA expression (Hiyama et al. 1995a; Hiyama et al. 1997a; Poremba et al. 1999b; Streutker et al. 2001; Krams et al. 2003) . Interestingly, in stage 4S neuroblastoma, which represents a unique entity characterized by a high frequency of spontaneous regression, telomeres were shortened and telomerase activity was undetectable (Hiyama et al. 1995a (Hiyama et al. , 1997a . Telomerase activity can also predict the outcomes of patients with gliomas, brain tumors that are consistently difficult to assign as either benign or malignant. Studies have shown that telomerase activity is present in most cases of malignant gliomas but is undetectable in grade I gliomas, making it a useful indicator of the malignant grade of gliomas (Nakatani et al. 1997; Huang et al. 1999) . In tumors of the thyroid gland, telomerase activity may be useful to distinguish benign from malignant tumors and might provide a useful indicator of prognosis (Haugen et al. 1997; Saji et al. 1997) . In pituitary adenoma, detection of telomerase expression may also correlate with biological aggressiveness and potential for regrowth (Yoshino et al. 2003) . Telomerase activity in bone marrow has recently been reported to be a highly significant prognostic factor in pediatric patients with acute myeloid leukemia (Verstovsek et al. 2003) . Collectively, these findings demonstrate that telomerase activity and hTERT expression are markers that can be used successfully to predict the outcome of cancer patients and take decisions on the appropriate treatments. , Alpha Diagnostic Int. Co., San Antonio, TX) was employed to reveal the presence of the hTERT protein in a FNA sample of a duct cell adenocarcinoma of the breast (a) and in a biopsy derived from an adenocarcinoma of the sigmoid colon (b). Tumor cells are revealed by the presence of brown pigments in the nucleus of hTERT-positive cells. Staining with 3,3¢-diaminobenzidine (DAB) was preformed as described previously (Hiyama et al. 2001) . The cells obtained from FNA sample were formalin-fixed and paraffin-embedded. For both samples, heat-based antigen retrieval was performed using a citrate buffer. 
Conclusion
In conclusion, measurement of telomerase activity and/or hTERT expression has several clinical utilities: for the early detection of cancer cells (in tumors that acquire telomerase activity at the early stages); as a prognostic indicator (in tumors that acquire telomerase activity upon progression); a marker that can distinguish malignancies from benign tumors; and a marker for detecting circulating cancer cells in the blood. In situ hybridization and the immunohistochemical detection of hTERT can now be used to identify telomerase-positive cancer cells in a background of non-cancerous cells. In the near future, methods for the in situ detection of hTERT are likely to become of common use in the clinics for both the diagnosis of cancers and the grading of malignancies.
